No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group
Table 1
Baseline characteristics of AML patients treated with GO 3 mg/m(2) during reinduction and consolidation phases based on CD33 rs12459419 polymorphism.
CD33 rs12459419 genotype in AML patients treated with GO in reinduction and consolidation phases
Reinduction treatment
Consolidation treatment
Patients characteristics
Total; n =20
CC (; 60%)
CT/TT (; 35%/5%)
Total;
CC (; 46%)
CT/TT (; 49%/6%)
Median age at diagnosis, years
51
49.5
53.9
57.2
57.2
57.7
Range
17.4–64.2
17.4-64.1
30.4-61.2
24.8–76.9
24.8-70.0
28.2-76.9
Median follow-up, years
0.58
0.58
0.25
2.13
1.96
2.17
Sex
Female
10 (50%)
8 (67%)
2 (25%)
36 (51%)
18 (56%)
18 (47%)
Male
10 (10%)
4 (33%)
6 (75%)
34 (49%)
14 (44%)
20 (53%)
Cytogenetic risk (ELN 2010)
Favorable risk
5 (25%)
4 (33%)
1 (13%)
28 (40%)
15 (47%)
13 (34%)
Intermediate-I risk
2 (10%)
2 (17%)
─
20 (29%)
8 (25%)
12 (32%)
Intermediate-II risk
6 (30%)
3 (25%)
3 (38%)
7 (10%)
3 (9%)
4 (11%)
Adverse risk
6 (30%)
3 (25%)
3 (38%)
9 (13%)
4 (13%)
5 (13%)
Median leucocytes at diagnosis, 109/L
14.7
16.0
22.8
17.5
17.5
17.5
Range
1.6-206.6
1.6-100.5
1.9-206.6
0,7-379
1,1-379
0,7-324
Median hemoglobin at diagnosis, g/dl
8.7
8.7
8.8
9.5
9,5
9,5
Range
4.6-11.2
4.6-11.2
5.5-10.9
5-13,9
5-13,9
5,3-13,5
Median platelets at diagnosis, 109/L
53
53
49
65
65
62
Range
15-261
30-261
15-97
14-336
14-317
13-336
Treatment
Induction therapy
Idarubicin+cytarabine ()
19 (95%)
11 (92%)
8 (100%)
59 (84%)
27 (84%)
32 (84%)
Idarubicin+cytarabine ()
1 (5%)
1 (8%)
─
9 (13%)
5 (16%)
4 (11%)
Other treatments
─
─
─
2 (3%)
─
2 (5%%)
Reinduction
with GO
1 (5%)
─
1 (12.5%)
─
─
─
IDA-FLAGO
19 (95%)
12 (100%)
7 (87.5%)
─
─
─
Other treatments
─
─
─
─
─
─
Consolidation
HDARAC+GO
─
─
─
14 (20%)
6 (19%)
8 (21%)
─
─
─
56 (80%)
26 (81%)
30 (79%)
HDARAC
6 (30%)
4 (33%)
2 (25%)
─
─
IDA-FLAG
2 (10%)
2 (17%)
─
─
─
Support treatment
1 (5%)
1 (8%)
─
─
─
Stem cell transplant
Allogeneic hematopoietic cell transplantation
11 (55%)
8 (67%)
3 (38%)
22 (31%)
11 (34%)
11 (29%)
Autologous hematopoietic cell transplantation
─
─
─
19 (27%)
6 (19%)
13 (29%)
Abbreviations: GO: gemtuzumab ozogamicin; ELN: European Leukemia Net; IDA-FLAG/IDA-FLAGO: idarubicin, fludarabine, cytarabine, and G-CSF ± GO; ARAC (100 mg/m2 during 5 days); HDARAC (1-3 g/m2 during 1, 3, and 5 days of the cycle).
